BIOMAT Database Logo BIOMAT Database Logo

MIF-1 potentiates the action of tricyclic antidepressants in an animal model of depression. 1991

W Kostowski, and W Danysz, and W Dyr, and E Jankowska, and P Krzaścik, and W Pałejko, and R Stefański, and A Płaźnik
Department of Pharmacology and Physiology of the Nervous System, Institute of Psychiatry and Neurology, Warszawa, Poland.

In the present paper, the effect of simultaneous treatment of rats with low doses of MIF-1 and tricyclic antidepressants on rat behavior in the forced swim test was studied. It was found that MIF-1 stimulated in a dose-dependent manner "active" behavior of animals in this paradigm. The effect of MIF-1 appeared to be independent of changes in rats' locomotion in the open field test. The combined treatment of rats with MIF-1 (0.01 mg/kg IP) and amitriptyline (5 mg/kg IP) or desipramine (1.25 mg/kg) IP) significantly stimulated active behavior in the forced swim test above the level obtained with each of the drugs given separately. The present data suggest the potential clinical efficacy of a combined therapy of depressive patients with MIF-1 and small doses of tricyclic antidepressants.

UI MeSH Term Description Entries
D008297 Male Males
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D009075 MSH Release-Inhibiting Hormone A hypothalamic tripeptide, enzymatic degradation product of OXYTOCIN, that inhibits the release of MELANOCYTE-STIMULATING HORMONES. MSH Release-Inhibiting Factor,Melanocyte-Stimulating Hormone Release-Inhibiting Hormone,Prolyl-Leucyl-Glycinamide,H-Pro-Leu-Gly-NH2,MIF-1,MIF-I,Melanocyte-Stimulating Hormone Release-Inhibiting Factor,Melanostatin,Oxytocin (7-9),Pro-Leu-Gly-NH2,Pro-Leu-Glyamide,Prol-Leu-Gly-NH2,Prolylleucylglycinamide,Prol Leu Gly NH2,Prolyl Leucyl Glycinamide
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D003891 Desipramine A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors. Desmethylimipramine,Apo-Desipramine,Demethylimipramine,Desipramine Hydrochloride,Norpramin,Novo-Desipramine,Nu-Desipramine,PMS-Desipramine,Pertofran,Pertofrane,Pertrofran,Petylyl,Ratio-Desipramine,Apo Desipramine,Hydrochloride, Desipramine,Novo Desipramine,Nu Desipramine,PMS Desipramine,Ratio Desipramine
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D000639 Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines. Amineurin,Amitrip,Amitriptylin Beta,Amitriptylin Desitin,Amitriptylin RPh,Amitriptylin-Neuraxpharm,Amitriptyline Hydrochloride,Amitrol,Anapsique,Apo-Amitriptyline,Damilen,Domical,Elavil,Endep,Laroxyl,Lentizol,Novoprotect,Saroten,Sarotex,Syneudon,Triptafen,Tryptanol,Tryptine,Tryptizol,Amitriptylin Neuraxpharm,Apo Amitriptyline,Desitin, Amitriptylin,RPh, Amitriptylin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

W Kostowski, and W Danysz, and W Dyr, and E Jankowska, and P Krzaścik, and W Pałejko, and R Stefański, and A Płaźnik
MIF-1 is active in a chronic stress animal model of depression.
March 1989, Pharmacology, biochemistry, and behavior,
W Kostowski, and W Danysz, and W Dyr, and E Jankowska, and P Krzaścik, and W Pałejko, and R Stefański, and A Płaźnik
Tricyclic antidepressants in the treatment of depression.
February 2000, Australian family physician,
W Kostowski, and W Danysz, and W Dyr, and E Jankowska, and P Krzaścik, and W Pałejko, and R Stefański, and A Płaźnik
Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression.
February 1987, European journal of pharmacology,
W Kostowski, and W Danysz, and W Dyr, and E Jankowska, and P Krzaścik, and W Pałejko, and R Stefański, and A Płaźnik
Depression resistant to tricyclic antidepressants.
October 1988, BMJ (Clinical research ed.),
W Kostowski, and W Danysz, and W Dyr, and E Jankowska, and P Krzaścik, and W Pałejko, and R Stefański, and A Płaźnik
Depression resistant to tricyclic antidepressants.
August 1988, BMJ (Clinical research ed.),
W Kostowski, and W Danysz, and W Dyr, and E Jankowska, and P Krzaścik, and W Pałejko, and R Stefański, and A Płaźnik
[Are tricyclic antidepressants unsuitable in depression?].
September 1997, Lakartidningen,
W Kostowski, and W Danysz, and W Dyr, and E Jankowska, and P Krzaścik, and W Pałejko, and R Stefański, and A Płaźnik
Tricyclic antidepressants in the treatment of poststroke depression.
July 1989, The Journal of clinical psychiatry,
W Kostowski, and W Danysz, and W Dyr, and E Jankowska, and P Krzaścik, and W Pałejko, and R Stefański, and A Płaźnik
Tricyclic antidepressants: evidence for an intraneuronal site of action.
April 1969, Science (New York, N.Y.),
W Kostowski, and W Danysz, and W Dyr, and E Jankowska, and P Krzaścik, and W Pałejko, and R Stefański, and A Płaźnik
[Mode of action of tricyclic antidepressants].
June 1973, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
W Kostowski, and W Danysz, and W Dyr, and E Jankowska, and P Krzaścik, and W Pałejko, and R Stefański, and A Płaźnik
Depression, heart disease, and tricyclic antidepressants.
July 1989, The Journal of clinical psychiatry,
Copied contents to your clipboard!